• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

围手术期循环肿瘤干细胞标志物表达增加预示肝细胞癌根治性切除术后早期复发

Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma.

作者信息

Choi Gi Hong, Kim Gwang Il, Yoo Jeong Eun, Na Deuk Chae, Han Dai Hoon, Roh Yun Ho, Park Young Nyun, Choi Jin Sub

机构信息

Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemoon-gu, Seoul, 120-752, Korea.

Yonsei Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1444-52. doi: 10.1245/s10434-015-4480-9. Epub 2015 Mar 20.

DOI:10.1245/s10434-015-4480-9
PMID:25791790
Abstract

BACKGROUND

This study was designed to investigate the correlation between postoperative recurrence of hepatocellular carcinoma (HCC) and perioperative expression and dynamic changes in cancer stem cell (CSC) markers in tumors and peripheral blood.

METHODS

In HCC patients who underwent curative resection (n = 64) or liver transplantation (LT) (n = 17), mRNA levels for K19, EpCAM, and CD44 in peripheral blood and HCC tissues before and after operation were examined using real-time RT-PCR. Postoperative recurrence was analyzed in patients who underwent resection. Study participants were divided into high and low ratio groups, according to the ratio of postoperative to preoperative mRNA levels for each marker.

RESULTS

K19 and CD44 mRNA levels in HCC tissues were higher in patients with recurrence than those without recurrence (p < 0.05 for all). Preoperative peripheral levels of K19 and EpCAM mRNA were higher in LT patients than in resection patients, and they were also significantly higher in cirrhotic patients of Child-Pugh Class B or C than those of Child-Pugh Class A (p < 0.05 for all). A high ratio of K19 mRNA was associated with lower relapse-free rate. Additionally, a high ratio for both K19 and CD44 mRNA was an independent poor prognostic factor for relapse-free survival (hazard ratio = 3.382, p = 0.016).

CONCLUSIONS

Preoperative peripheral levels of K19 and EpCAM mRNA were influenced by background liver status and HCC. Additionally, the ratio of postoperative to preoperative mRNA levels for CSC markers, especially K19 and CD44, was shown to be important to predict HCC recurrence.

摘要

背景

本研究旨在探讨肝细胞癌(HCC)术后复发与肿瘤及外周血中癌干细胞(CSC)标志物的围手术期表达及动态变化之间的相关性。

方法

对64例行根治性切除术或17例行肝移植(LT)的HCC患者,采用实时逆转录聚合酶链反应检测手术前后外周血及HCC组织中K19、EpCAM和CD44的mRNA水平。对接受切除术的患者进行术后复发分析。根据每个标志物术后与术前mRNA水平的比值,将研究参与者分为高比值组和低比值组。

结果

复发患者HCC组织中K19和CD44的mRNA水平高于未复发患者(均p < 0.05)。LT患者术前外周血K19和EpCAM的mRNA水平高于接受切除术的患者,Child-Pugh B级或C级肝硬化患者也显著高于Child-Pugh A级患者(均p < 0.05)。K19 mRNA高比值与较低的无复发生存率相关。此外,K19和CD44 mRNA均高比值是无复发生存的独立不良预后因素(风险比 = 3.382,p = 0.016)。

结论

术前外周血K19和EpCAM的mRNA水平受肝脏背景状态和HCC的影响。此外,CSC标志物术后与术前mRNA水平的比值,尤其是K19和CD44,对预测HCC复发很重要。

相似文献

1
Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma.围手术期循环肿瘤干细胞标志物表达增加预示肝细胞癌根治性切除术后早期复发
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1444-52. doi: 10.1245/s10434-015-4480-9. Epub 2015 Mar 20.
2
Preoperative peripheral blood human telomerase reverse transcriptase mRNA concentration is not a prognostic factor for resection of hepatocellular carcinoma.术前外周血人端粒酶逆转录酶mRNA浓度不是肝细胞癌切除术的预后因素。
Hepatogastroenterology. 2012 Jul-Aug;59(117):1512-5. doi: 10.5754/hge10342.
3
Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy.缺氧诱导因子-1和上皮细胞粘附分子的表达与肝细胞癌射频消融治疗后侵袭性局部复发相关。
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S436-42. doi: 10.1245/s10434-014-3575-z. Epub 2014 Feb 25.
4
Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.黏着连接相关蛋白1表达降低预示根治性肝切除术后肝细胞癌复发
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1499-507. doi: 10.1245/s10434-015-4695-9. Epub 2015 Jun 30.
5
Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.术前上皮细胞黏附分子循环肿瘤细胞及外周调节性T细胞水平与肝癌根治性肝切除术后早期复发的相关性
BMC Cancer. 2016 Jul 20;16:506. doi: 10.1186/s12885-016-2526-4.
6
[Correlation of perioperative alpha-fetoprotein expression in peripheral blood to recurrence of hepatocellular carcinoma].[围手术期外周血甲胎蛋白表达与肝细胞癌复发的相关性]
Ai Zheng. 2008 Jan;27(1):83-7.
7
Does surgical resection of hepatocellular carcinoma accelerate cancer dissemination?肝细胞癌的手术切除会加速癌症扩散吗?
World J Gastroenterol. 2004 Jan;10(1):31-6. doi: 10.3748/wjg.v10.i1.31.
8
Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.SAMSN1表达的抑制与肝细胞癌的恶性表型相关。
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1453-60. doi: 10.1245/s10434-015-4524-1. Epub 2015 Mar 25.
9
Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.CDX1低表达预示着肝癌患者肝切除术后预后不良。
Surg Oncol. 2016 Sep;25(3):171-7. doi: 10.1016/j.suronc.2016.05.026. Epub 2016 May 24.
10
AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma.通过实时定量逆转录聚合酶链反应分析在骨髓中检测到的甲胎蛋白信使核糖核酸可预测肝细胞癌根治性肝切除术后的生存率和复发情况。
Ann Surg. 2006 Sep;244(3):451-63. doi: 10.1097/01.sla.0000234840.74526.2b.

引用本文的文献

1
Liquid Biopsy in Hepatocellular Carcinoma: ctDNA as a Potential Biomarker for Diagnosis and Prognosis.肝细胞癌中的液体活检:循环肿瘤DNA作为诊断和预后的潜在生物标志物
Curr Oncol Rep. 2025 May 9. doi: 10.1007/s11912-025-01681-3.
2
Beyond graft function impairment after liver transplantation: the prolonged cold ischemia time impact on recurrence of hepatocellular carcinoma after liver transplantation-a single-center retrospective study.肝移植后除移植物功能损害以外:冷缺血时间延长对肝移植后肝细胞癌复发的影响——一项单中心回顾性研究。
PeerJ. 2024 Oct 4;12:e18126. doi: 10.7717/peerj.18126. eCollection 2024.
3
The CD44s Isoform is a Potential Biomarker for Predicting Craniopharyngioma Recurrence in Children.
CD44s 异构体是预测儿童颅咽管瘤复发的潜在生物标志物。
Neuromolecular Med. 2024 Jul 17;26(1):30. doi: 10.1007/s12017-024-08797-y.
4
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.预测肝细胞癌患者免疫检查点抑制剂治疗反应的生物标志物。
Int J Mol Sci. 2023 Apr 21;24(8):7640. doi: 10.3390/ijms24087640.
5
Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?液体活检会成为肝细胞癌肝移植决策的未来转向器吗?
Front Oncol. 2022 Aug 11;12:940473. doi: 10.3389/fonc.2022.940473. eCollection 2022.
6
Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation.循环肿瘤干细胞表达 EpCAM/CD90 在肝癌中的研究:一项预测活体肝移植后肿瘤复发的初步研究。
Gut Liver. 2022 May 15;16(3):443-455. doi: 10.5009/gnl210162.
7
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.肝细胞癌根治性治疗后的免疫标志物、预后因素及挑战
Int J Mol Sci. 2021 Sep 24;22(19):10271. doi: 10.3390/ijms221910271.
8
Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression.伴有角蛋白19表达的肝细胞癌的临床-放射-病理及分子特征
Liver Cancer. 2020 Dec;9(6):663-681. doi: 10.1159/000510522. Epub 2020 Oct 23.
9
Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis.循环肿瘤细胞在肝细胞癌(HCC)诊断和预后中的临床价值:一项系统评价和荟萃分析
Medicine (Baltimore). 2020 Oct 2;99(40):e22242. doi: 10.1097/MD.0000000000022242.
10
Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.癌症干细胞的起源和生物标志物:靶向个体化治疗的新视角。
Front Immunol. 2020 Aug 7;11:1280. doi: 10.3389/fimmu.2020.01280. eCollection 2020.